Nextera Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 5

Nextera General Information

Description

Developer of an antibody discovery platform designed to identify therapeutic antibodies targeting intracellular disease markers. The company offers TCR-like antibody discovery capabilities targeting peptide-human leukocyte antigen complexes and access to intracellular targets through class I and class II presentation, enabling biopharmaceutical companies and therapeutic developers to advance treatments for autoimmune and oncology indications. Developer of an antibody discovery platform designed to identify antibodies targeting peptide-human leukocyte antigen complexes for therapeutic development. The company's platform offers TCR-like antibody discovery capabilities, access to intracellular targets through class I and class II peptide-human leukocyte antigen presentation, and collaborative drug development support, enabling biotechnology and pharmaceutical companies to develop therapies for autoimmune and oncology indications.

Contact Information

Website
www.nextera.no
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Oslo Tech
  • Gaustadalléen 21
  • 0349 Oslo
  • Norway
+47 93
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Oslo Tech
  • Gaustadalléen 21
  • 0349 Oslo
  • Norway
+47 93

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nextera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Accelerator/Incubator Completed Product Development
8. Secondary Transaction - Private 01-Apr-2021 Completed Product Development
7. Grant 01-Feb-2016 Completed Product Development
6. Early Stage VC 19-Aug-2012 Completed Startup
5. Secondary Transaction - Private 04-Jul-2012 Completed Startup
4. Early Stage VC 01-May-2011 Completed Startup
3. Early Stage VC 06-Dec-2010 Completed Startup
2. Early Stage VC 01-Aug-2009 Completed Startup
1. University Spin-Out 01-Jan-2009 Completed Startup
To view Nextera’s complete valuation and funding history, request access »

Nextera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an antibody discovery platform designed to identify therapeutic antibodies targeting intracellular disease
Drug Discovery
Oslo, Norway
11 As of 2026

Abingdon, United Kingdom
 

Porto, Portugal
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nextera Competitors (7)

One of Nextera’s 7 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Fairjourney Biologics Private Equity-Backed Porto, Portugal
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
.Avidity Corporation Aurora, CO
Alloy Therapeutics Venture Capital-Backed Waltham, MA
You’re viewing 5 of 7 competitors. Get the full list »

Nextera Patents

Nextera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202409181-D0 Antigen binding proteins Inactive 26-Jun-2024
GB-202409182-D0 Antigen binding proteins Inactive 26-Jun-2024
EP-4827929-A1 Antibody conjugate Pending 22-Dec-2023
GB-202319932-D0 Antibody conjugate Inactive 22-Dec-2023
WO-2025133346-A1 Antibody conjugate Inactive 22-Dec-2023 A61P37/06
To view Nextera’s complete patent history, request access »

Nextera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nextera Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Research Council of Norway Government
Radforsk Investeringsstiftelse Venture Capital Minority
Birk Venture Venture Capital Minority
University of Oslo University
ShareLab Incubator Accelerator/Incubator
To view Nextera’s complete investors history, request access »

Nextera FAQs

  • When was Nextera founded?

    Nextera was founded in 2009.

  • Where is Nextera headquartered?

    Nextera is headquartered in Oslo, Norway.

  • What is the size of Nextera?

    Nextera has 11 total employees.

  • What industry is Nextera in?

    Nextera’s primary industry is Drug Discovery.

  • Is Nextera a private or public company?

    Nextera is a Private company.

  • What is Nextera’s current revenue?

    The current revenue for Nextera is .

  • Who are Nextera’s investors?

    Research Council of Norway, Radforsk Investeringsstiftelse, Birk Venture, University of Oslo, and ShareLab Incubator have invested in Nextera.

  • Who are Nextera’s competitors?

    Adaptimmune Therapeutics, Fairjourney Biologics, Immunocore Holdings, .Avidity, and Alloy Therapeutics are some of the 7 competitors of Nextera.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process